Conference abstract · 26 Jan 2021
Conference abstractPublished 15 Oct 2018
The key to Manufacturing Viral Vaccines for individual Human Population
Rangsit University, Thailand
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nowadays, subunit viral vaccine becomes the major choice for manufacturing viral vaccine with a thought of safety reason to prevent side effects. However, the success to use subunit viral vaccine to prevent a particular viral infection is very limit. This is different from the time when Cowpox virus was originally used for vaccination to prevent the smallpox viral epidemic over a century ago. Although the knowledge of immunity has been discovered a lot more than the Edward Jenner’s period, the effectiveness of viral vaccine could not reach our accomplishment. Accordingly, we need to revise our knowledge and manipulate in the right direction for the viral vaccine production. Basically, to induce an immunity to prevent a viral infection, our body must produce a specific antibody which needs induction not only by a particular viral antigen but also the molecules called major histocompatibility complex (MHC). Each molecule of MHC alleles plays a key role in the immune response by forming a specific complex with its appropriate epitope to induce a specific T cell clone thru its specific receptor. MHC class I is required for inducing cytotoxic T cell while MHC class II is for helper T cell. Helper T cell plays a key role to induce an effective stage of acquired immunity especially a specific antibody which is believed to be a gearwheel to prevent an invasion of the particular viral particle. To produce the viral-specific antibody, MHC class II plays a key role to induce helper T cell and then B cell to synthesize a specific antibody. Since the MHC gene alleles are highly polymorphic so the possibility that individuals have the same gene alleles might be one in a million which, mostly, can be found in those who are an identical twin. Accordingly, a subunit viral vaccine, which contains a limit number of epitopes, would reduce a capacity of an antigen presenting cell, such as a dendritic cell, to process some epitopes to induce the particular helper T cell clones. Subsequently, the corresponding B cell clones cannot synthesize the specific antibody to neutralize the particular infectious viral particle. Accordingly, this presentation will present a different notion and principle to develop a viral vaccine for an individual human population.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2019
The keys to manufacturing viral vaccines for individual human population
Short communication · 25 Dec 2020
The explanations to developed viral vaccines for individual human population
Conference abstract · 23 Mar 2022
Early proof of concept with human viral challenge models in vaccine development
Short communication · 22 Jun 2018
Early proof of concept with human viral challenge models in vaccine development
More from this journal
The newest in Clinical Pharmacology & Biopharmaceutics.
Research article · 27 Jul 2026
Qualitative LC/MS Assessment of Fenfluramine Hydrochloride After Dilution in Purified Water : A Preliminary Study and Case Report
Article · 20 Jul 2026
Population Pharmacology: Precision Dosing for Diverse Patients
Article · 17 Jul 2026
Therapeutic Drug Monitoring: Optimizing Therapy, Minimizing Toxicity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tirasak Pasharawipas”
